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Tolerogenic dendritic cells (TolDCs) are promising tools for therapy of autoimmune dis-
eases, such as rheumatoid arthritis (RA). Here, we characterize monocyte-derived TolDCs 
from RA patients modulated with dexamethasone and activated with monophosphoryl 
lipid A (MPLA), referred to as MPLA-tDCs, in terms of gene expression, phenotype, 
cytokine profile, migratory properties, and T cell-stimulatory capacity in order to explore 
their suitability for cellular therapy. MPLA-tDCs derived from RA patients displayed 
an  anti-inflammatory profile with reduced expression of co-stimulatory molecules and 
high IL-10/IL-12 ratio, but were capable of migrating toward the lymphoid chemokines 
CXCL12 and CCL19. These MPLA-tDCs induced hyporesponsiveness of autologous 
CD4+ T cells specific for synovial antigens in vitro. Global transcriptome analysis con-
firmed a unique transcriptional profile of MPLA-tDCs and revealed that RA-associated 
Abbreviations: ACR, American College of Rheumatology; CCR7, chemokine receptor 7; CFSE, carboxyfluorescein diacetate 
succinimidyl ester; CXCR4, chemokine receptor 4; CXB, celecoxib; DCs, dendritic cells; ELISA, enzyme linked immune-
sorbent assay; FBS, fetal bovine serum; HCQ, hydroxychloroquine; IFN-γ, interferon-γ; IL, interleukin; LFN, leflunomide; 
LPS, lipopolysaccharide; MEL, meloxicam; MHC, major histocompatibility complex; MPLA, monophosphoryl lipid A; MPLA-
tDCs, dexamethasone and monophosphoryl lipid A treated dendritic cells; MPSL, methylprednisolone; MTX, methotrexate; 
NSAID, non-steroidal anti-inflammatory drugs; PDN, prednisone; RA, rheumatoid arthritis; rhGM-CSF, recombinant human 
granulocyte-macrophage colony stimulating factor; SF, synovial fluid; TGF-β, transforming growth factor beta; TLR2, toll-like 
receptor 2; TolDCs, tolerogenic dendritic cells; Treg, regulatory T cells.
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genes, which were upregulated in untreated DCs from RA patients, returned to expres-
sion levels of healthy donor-derived DCs after treatment with dexamethasone and MPLA. 
Thus, monocyte-derived DCs from RA patients have the capacity to develop tolerogenic 
features at transcriptional as well as at translational level, when modulated with dexa-
methasone and MPLA, overcoming disease-related effects. Furthermore, the ability of 
MPLA-tDCs to impair T cell responses to synovial antigens validates their potential as 
cellular treatment for RA.
Keywords: rheumatoid arthritis, dendritic cells, tolerance, cell-based therapy, transcriptome
inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic autoimmune disease 
characterized by the inflammation of synovial tissue, which leads 
to progressive cartilage and bone destruction. The development 
of RA is attributed to an uncontrolled activation of auto-reactive 
CD4+ T cells (1, 2). Dendritic cells (DCs) play a pivotal role in the 
pathogenesis of RA through presentation of autoantigen peptides 
on major histocompatibility complex (MHC) molecules (3, 4). 
The secretion of pro-inflammatory cytokines by DCs further 
promotes the maturation of bystander DCs and drives the dif-
ferentiation of T helper type 1 (Th1) and Th17 cells, both involved 
in the pathology and progression of RA (1, 2).
Current treatment of RA includes the use of immunosuppres-
sive drugs and/or biologic therapies (2, 5). All of them require 
lifelong treatment and, thus, new therapeutic strategies are 
needed to suppress inflammation and re-establish self-tolerance 
without affecting the whole patient’s immune system. In par-
ticular, research has focused on the generation of tolerogenic 
DCs (TolDCs) capable of modulating antigen-specific immune 
responses (6, 7). TolDCs may induce antigen-specific tolerance 
through induction of anergy, deletion of auto-reactive T cells 
(8,  9), generation and expansion of regulatory T cells (Treg) 
(10, 11), and/or the establishment of an anti-inflammatory envi-
ronment through secretion of IL-10 and/or transforming growth 
factor beta (TGF-β) (12).
Different strategies have been described for the in vitro genera-
tion of TolDCs derived from peripheral blood monocytes, includ-
ing modulation by IL-10 or TGF-β (8, 13), dexamethasone (14), 
Bay11-7082 (15), rapamycin (16), aspirin (17) or vitamin D3 (18), 
short stimulation with lipopolysaccharide (LPS) (19), or its non-
toxic analog monophosphoryl lipid A (MPLA) (20). Although 
TolDC properties may vary according to the applied protocol, 
TolDC features include reduced expression of co-stimulatory and 
antigen presentation molecules, low IL-12 production, and sup-
pression of effector T cell responses in vitro (21, 22). Application 
of TolDCs for RA treatment has been successfully tested in ani-
mal models (23, 24). Phase I clinical trials using in vitro modified 
autologous TolDCs demonstrated feasibility and safety in patients 
with type 1 diabetes (25) and RA (15, 26).
Recently, we described a shortened protocol for the differen-
tiation of monocytes from healthy donors into TolDCs, using 
dexamethasone for immunomodulation, and current good 
manufacture practice (cGMP)-grade MPLA to trigger toll-like 
receptor (TLR)-mediated activation, including the upregulation 
of chemokine receptors that mediate the migration to secondary 
lymphoid organs (20). These MPLA-tDCs expressed low levels 
of co-stimulatory molecules and maturation markers, and 
secreted high levels of IL-10 and low levels of IL-12. In functional 
analyses, they migrated to lymphoid chemokines and induced 
lower levels of T cell proliferation and cytokine production than 
mature DCs (27).
Monocytes from RA patients were demonstrated to exhibit 
a highly inflammatory profile (28, 29) and studies investigating 
their capacity to develop into functional TolDCs in vitro showed 
contradictory results (30, 31), suggesting that disease-associated 
factors might affect TolDC differentiation. To date, there are no 
studies comparing the transcriptomes of immature, mature, and 
modulated monocyte-derived DCs (moDCs) from RA patients 
and healthy subjects.
Therefore, the aim of the present study was to translate our 
MPLA-tDC protocol to moDCs derived from RA patients, and to 
characterize them at phenotypic, functional, and transcriptional 
level in order to validate their applicability as autologous cellular 
therapy to restore antigen-specific tolerance in RA.
MaTerials anD MeThODs
The minimum information about tolerogenic antigen-presenting 
cells (MITAP) checklist (32) was followed for the preparation of 
this manuscript.
Blood samples and synovial Fluid
Twenty-seven leukapheresates from patients with active RA and 
28 buffy coats from healthy donors were obtained from Hospital 
del Salvador and Hospital Clínico de la Universidad de Chile. 
Demographic characteristics of patients and healthy donors are 
detailed in Table S1 in Supplementary Material. All RA patients 
fulfilled ACR criteria for RA diagnosis and received treatment 
as described in Table S1 in Supplementary Material. Subjects 
signed an informed written consent according to the Declaration 
of Helsinki and all procedures were approved by the Ethics 
Committees of the Facultad de Medicina and Hospital Clínico 
from Universidad de Chile, and Hospital del Salvador.
Synovial fluid (SF) was collected through arthrocentesis of 
inflamed knees of one RA patient. Removal of cells from SF was 
done by centrifugation at 1800 rpm for 5 min. The acellular frac-
tion was treated with hyaluronidase (100  U/ml) for 60  min at 
37°C to reduce viscosity and centrifuged at 1800 rpm for 10 min 
before passing through a 0.2-μm filter. Protein concentration was 
quantified using the BCA method (Sigma-Aldrich, MO, USA) at 
A562 (Table S1 in Supplementary Material).
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generation of Monocyte-Derived Dcs
Monocytes were isolated by negative selection using RosetteSep 
Human Monocyte enrichment cocktail (Stemcell Technologies, 
Vancouver, BC, Canada) according to manufacturer’s instruc-
tions. moDCs were generated as previously described (20) in 
AIM-V medium (Gibco BLR, Grand Island, NE, USA), sup-
plemented with 500 U/ml of recombinant human GM-CSF and 
IL-4 (eBioscience, San Diego, CA, USA) within 5 days. At days 3 
and 4, cells were modulated with 1 μM dexamethasone (tDCs) 
(Sigma-Aldrich, St. Louis, MO, USA) and activated with 1 μg/
ml cGMP-grade MPLA (MPLA-tDCs) (Avanti, Alabaster, AL, 
USA). Untreated/immature DCs (iDCs) and MPLA-matured 
DCs (mDCs) were used as controls.
Flow cytometry
Antibodies used for analysis were anti-human CD11c APC, CD80 
FITC, CD83 FITC, HLA-DR FITC, CD40 PE, CD86 PE, TLR-2 
PE, CXCR4 PE, CCR7 PE, CD4 PECy7, and IFN-γ APC (all 
from eBioscience). Cells were resuspended in PBS supplemented 
with fetal bovine serum (FBS) (HyClone Thermo Scientific, 
Logan, UT, USA), stained with specific antibodies, fixed with 
IC fixation buffer (eBioscience) and resuspended in FACSFlow 
buffer (Becton Dickinson, San Diego, CA, USA) for subsequent 
analysis. Data were acquired on a FACSAria III with FACSDiva 
v6.1.3 software (both Becton Dickinson) and analyzed by FlowJo 
software (Treestar, USA).
cytokine Production
1 ×  105 DCs were incubated for 24 h with or without CD40L-
transfected irradiated NIH3T3 cells at 1:1 ratio in AIM-V medium 
in 96-well U bottom plates (BRAND, Wertheim, Germany). 
Supernatants of co-cultures with NIH3T3 cells or T  cells were 
recovered and stored at −80°C until quantification of IL-10, 
IL-12p70, IL-23, TNF-α, TGF-β1(active), and IL-17A by ELISA 
(eBioscience).
chemotaxis assay
Migration was assessed in vitro using a transwell system (24-well, 
pore size 5  μm polycarbonate inserts; Corning Costar, USA). 
1.5 × 105 DCs from RA patients were seeded in the upper cham-
ber and AIM-V medium alone or supplemented with 250 ng/ml 
of SDF-1α/CXCL12 or MIP-3β/CCL19 (PeproTech, Rocky Hill, 
CT, USA) was added to the lower chamber. After 4-h incubation 
at 37°C and 5% CO2, DCs in the lower chamber were counted by 
flow cytometry. DCs migration is expressed as “migration index” 
(migration toward chemokines/migration toward medium).
assessment of cD4+ T cell-stimulatory 
capacity of Dcs
CD4+ T cells were isolated by negative selection using RosetteSep 
Human T cell enrichment cocktail (Stemcell Technologies, 
Vancouver, BC, Canada) and labeled with carboxyfluorescein 
diacetate succinimidyl ester (CFSE).
For allogeneic assays, DCs from RA patients were co-cultured 
with CD4+ T cells from healthy donors. For assessment of 
antigen-specific CD4+ T cell activation, DCs from RA patients, 
loaded with 1 μg/ml tuberculin purified protein derivative (PPD; 
Staten Serum Institute, Copenhagen, Denmark) or 200  μg/ml 
SF proteins 4 h prior to activation with MPLA, were co-cultured 
with autologous CD4+ T cells at a DC:T cell ratio of 1:2 in RPMI 
medium (HyClone Thermo Scientific) with 10% FBS in 96-well U 
bottom plates for 6 days (20). CD4+ T cells alone, or stimulated 
with anti-human CD3 (eBioscience) were used as negative and 
positive controls, respectively. Supernatants were collected to 
assess cytokine secretion. For intracellular IFN-γ detection, 50 ng/
ml phorbol-12-myriastate-13-acetate (PMA, Sigma-Aldrich), 
1 μg/ml ionomycin (Sigma-Aldrich), and 1 μg/ml brefeldin-A 
(eBioscience) were added for the last 5 h of culture. Proliferation 
and IFN-γ production of CD4+ T cells were analyzed by flow 
cytometry.
rna isolation and Microarray analysis
Total RNA was isolated from 5 ×  105 moDCs using RNeasy 
Mini Kit (Qiagen, Hilden, Germany) according to manufac-
turer’s instructions. Yield and quality of RNA samples were 
evaluated with NanoDrop 1000 spectrophotometer (Thermo 
Scientific, Waltham, MA, USA) and RNA Integrity (RIN 
score) was analyzed with Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA) or LabChip GX/GX II 
(Caliper LifeSciences, Hopkinton, MA USA). A total of 76 
samples, corresponding to DCs derived from 9 RA patients 
and 10 healthy donors under 4 experimental conditions were 
considered for microarray analysis (Figure S1 in Supplementary 
Material). All RNA samples used for microarrays showed A260/
A280 values between 1.8 and 2.2, and RIN scores >7. RNA 
samples were reverse transcribed, amplified, and labeled using 
a Illumina® TotalPrepTM RNA Amplification Kit, and cRNA 
was hybridized onto Illumina Human HT-12 v4 BeadChips 
(Illumina, San Diego, CA, USA), covering the whole human 
genome. Expression data were extracted with GenomeStudio 
Project Software from Illumina.
Data exploration and statistical Methods
Friedman repeated measures test (differences between culture 
conditions) or Kruskal–Wallis test (differences between RA 
patients and healthy donors) and Dunn’s post test were used for 
comparisons. Wilcoxon signed-rank test was used to compare 
migration of different DC populations. Analyses were performed 
using Prism 5.01 software (Graphpad, San Diego, CA, USA). 
P-values ≤0.05 were considered significant.
Microarray data were log-transformed and normalized 
using the preprocess Core package v1.28.0 from Bioconductor. 
Principal component analysis (PCA) was performed using the 
PCA function of mixOmics package v5.0-3 (33) of R software 
(34), in order to assess differences in differentiation protocols 
and to detect outliers that might affect downstream analyses. 
Differentially expressed (DE) genes in modulated DCs compared 
to unstimulated DCs (iDCs) were identified with the Maanova 
package v1.36.0 T-test for gene pairwise comparisons (35). 
A false discovery rate (FDR) of 0.05 or lower was used as cut-off 
value. K-means clustering of DE genes between MPLA-tDCS and 
iDCs was performed using the cluster package. Detailed analyses 
are described in Figure S1 in Supplementary Material.
FigUre 1 | MPla-tDcs from rheumatoid arthritis patients and healthy controls display a tolerogenic phenotype that remains unaffected under 
pro-inflammatory conditions. (a) Monocytes from patients with rheumatoid arthritis (RA) (black closed symbols) and from healthy control (HC) subjects (gray 
open symbols) were differentiated into DCs in the presence of GM-CSF and IL-4 within 5 days. For tolerization, DCs were conditioned with dexamethasone (Dex) 
during 48 h and were additionally activated with MPLA for the last 24 h of culture (MPLA-tDCs). Surface expression levels of CD86, CD40, CD83, HLA-DR, and 
TLR2 were assessed by flow cytometry. Dot plots show all data points and median values are indicated as a line. (B) MPLA-tDCs from RA patients were incubated 
for 72 h in the presence of synovial fluid (200 μg/ml) or TNFα (10 ng/ml), and the expression of phenotypic markers was analyzed. Untreated iDCs were used as 
controls. Statistical differences were calculated using either Kruskal–Wallis test (comparison between HC and RA) or Friedman test (comparison between culture 
conditions) and Dunn’s multiple comparison was used as post test (*P < 0.05; **P < 0.01; ***P < 0.001).
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resUlTs
MPla-tDcs from ra Patients exhibit a 
Tolerogenic Phenotype
The phenotype of different DCs subsets, generated from mono-
cytes of RA patients and healthy subjects was analyzed by flow 
cytometry. All DC populations contained >95% CD11c+ cells 
and exhibited high CD1a and low CD14 expression, while their 
viability ranged from 70 to 90% and did not differ between RA 
patients and healthy donors (data not shown). In comparison 
to mDCs, dexamethasone-treated and MPLA-activated DCs 
(MPLA-tDCs) showed reduced expression of CD86 and CD83, 
similar to iDCs (Figure 1A). Expression of CD40 and CD80 was 
also reduced in MPLA-tDCs compared to mDCs (Figure 1A and 
FigUre 2 | MPla-tDcs from rheumatoid arthritis patients exhibit an anti-inflammatory cytokine profile. Monocyte-derived DC (moDC) subsets from 
rheumatoid arthritis (RA) patients (black closed symbols) and healthy control subjects (HC; gray open symbols) were cultured with CD40L-transfected NIH3T3 cells 
at 1:1 ratio for 24 h. (a) Concentrations of IL-10, IL-12, IL-23, TNF-α, and active TGF-β1 were determined in culture supernatants of moDCs by ELISA. (B) Bar chart 
with values of IL-10/IL-12 ratio of different moDC subsets from RA patients. Dot plots show all data points and horizontal lines indicate median values. Statistical 
differences were calculated using Kruskal–Wallis test (comparison of HC and RA) or Friedman test (comparison of DC types) and Dunn’s multiple comparison post 
test (*P < 0.05; **P < 0.01; ***P < 0.001).
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data not shown). In accordance with the previously described 
elevated expression of TLR2 on TolDC generated with dexa-
methasone, vitamin D3, and MPLA (31), we observed that TLR2 
expression was significantly increased on MPLA-tDCs as com-
pared to iDCs and mDCs (Figure 1A). No significant differences 
were found concerning the phenotype of DC subsets between 
healthy subjects and RA patients (Figure  1A). Furthermore, 
exposure of RA-derived MPLA-tDCs to inflammatory stimuli, 
such as SF or TNF, did not affect the tolerogenic phenotype of 
these cells (Figure 1B).
MPla-tDcs from ra Patients show an 
anti-inflammatory cytokine Profile
Consistent with our previous findings in healthy subjects (20), we 
found that MPLA-tDCs from RA patients produced 10-fold more 
IL-10 and 5-fold less IL-12p70 than mDCs in response to CD40 
ligation (Figure  2). Although IL-10 levels tended to be higher 
in DCs from RA patients than in those from healthy subjects, 
these differences were not significant. MPLA-tDCs secreted 
significantly lower levels of TNF-α and IL-23 and higher levels 
of TGF-β1 than mDCs. The cytokine profiles of MPLA-tDCs 
and iDCs derived from RA patients were similar to those from 
healthy donors (Figure 2). Interestingly, the rate of IL-10/IL-12 
in MPLA-tDCs from RA patients was significantly higher than 
that observed in mDCs (Figure  2B). Mirroring their behavior 
toward SF and TNFα exposure, MPLA-tDCs maintained their 
low expression of CD86, CD80, CD40, and CD83, and the high 
expression of TLR2 upon CD40 engagement (data not shown).
MPla-tDcs from ra Patients Migrate 
toward secondary lymphoid Tissue 
chemokines
We investigated the expression of lymph node homing chemokine 
receptors on DCs from RA patients and their migratory response 
toward the corresponding chemokines in a transwell system. 
Expression of CXCR4 and CCR7 was 2.5 fold higher on MPLA-
tDCs than in iDCs and significantly enhanced when compared 
to tDCs (Figure  3A). MPLA-tDCs and mDCs also showed 
high migration indexes toward the CXCR4 and CCR7 ligands, 
CXCL12 and CCL19, respectively, exhibiting a higher migratory 
ability towards lymphoid chemokines than tDCs (Figure 3B).
MPla-tDcs from ra Patients Modulate 
allogeneic and autologous T cell 
responses
In order to evaluate T cell responses, MPLA-tDCs, mDCs, 
or iDCs of RA patients were cultured with allogeneic CD4+ 
FigUre 3 | MPla-tDcs from rheumatoid arthritis patients display the 
capacity to migrate toward ccr7 and cXcr4 ligands. After 5 days of 
culture, the migratory capacity of MPLA-tDC (dark gray), tDCs (white) and 
mDCs (light gray) from rheumatoid arthritis (RA) patients was studied in vitro. 
(a) The percentage of CD11c+ DCs expressing CXCR4 or CCR7 was 
determined by flow cytometry (n = 15). Fold expression changes on receptor 
expression on mDCs, tDCs and MPLA-tDCs compared to untreated iDCs are 
shown. (B) Transwell assays were used to assess migration of DCs in 
response to 250 ng/ml of CXCL12 or CCL19 (n = 12). Migration index 
indicates the quotient of cells that migrated toward a specific chemokine 
divided by cells that migrated toward medium alone. Box plots show median, 
25- and 75%-quartile, minimum and maximum values, respectively. Wilcoxon 
signed-rank test was used to evaluate statistical differences between 
MPLA-tDCs, tDCs, and mDCs (*P < 0.05; **P < 0.01; ***P < 0.001).
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T cells from healthy donors in mixed leukocyte reactions. 
When compared to mDCs, CD4+ T cell proliferative 
responses (median %CFSElowCD4+ T cells in co-cultures 
with: iDCs = 13.9; mDCs = 65.4; MPLA-tDCs = 22.8; mDCs 
vs. MPLA-tDCs: P =  0.001) and IFN-γ production (median 
%IFN-γ  +  CFSElowCD4+ T cells in co-cultures with: 
iDCs  =  3.4; mDCs  =  29.7; MPLA-tDCs  =  3.0; mDCs vs. 
MPLA-tDCs: P  =  0.005) to MPLA-tDCs were significantly 
reduced (Figure 4).
To investigate the capacity of MPLA-tDCs to present antigens 
and thereby activate antigen-specific memory T cells, DCs 
from RA patients were loaded with PPD or SF and co-cultured 
with autologous CD4+ T cells. While mDCs induced potent 
proliferation and IFN-γ production of CD4+ T cells, MPLA-
tDCs stimulated poor proliferation and IFN-γ expression in 
SF-specific CD4+ T cells (Figures 4A,B). Only mDCs but not 
MPLA-tDCs induced the secretion of IL-17A by SF-specific 
CD4+ T cells (Figure 4C). Proliferation, IFN-γ production, and 
IL-17A secretion of CD4+ T cells in co-culture with PPD-loaded 
MPLA-tDCs were slightly, but not significantly lower than those 
in co-culture with PPD-loaded mDCs (Figures  4B,C). Taken 
together, these results show that MPLA-tDCs obtained from 
RA patients have an impaired capacity to induce inflammatory 
CD4+ T cell responses.
Modulation with Dexamethasone and 
MPla generates a Particular 
Transcriptional Profile in Dcs, Which 
Overcomes ra-associated effects
To confirm that modulation with dexamethasone and MPLA 
confers tolerogenic features to DCs, regardless of whether they 
are derived from healthy subjects or RA patients, we analyzed 
transcriptomes of four different DC preparations, generated 
from monocytes of healthy donors and RA patients. RNA 
samples from different DCs preparations were subjected to 
whole-genome microarray analysis and DE genes between 
samples were defined by FDR of 0.05 or lower (Figure S1 in 
Supplementary Material). First, we investigated the effect of 
different stimuli for DC generation/modulation (“protocol”), 
health state of the donor (“disease”), or the combination of 
both (“interaction”), on gene expression (Figure 5). The differ-
entiation protocol (unstimulated: iDCs, dexamethasone: tDCs, 
MPLA: mDCs, and dexamethasone plus MPLA: MPLA-tDCs) 
had the main impact on gene expression, affecting 43% of the 
DC transcriptome (Figure  5A). The “disease” factor alone 
did not affect global gene expression, while the expression of 
11 transcripts was altered by a disease–protocol interaction 
(Figure  5A; Table S2 in Supplementary Material). This was 
in agreement with a Principal Component Analysis (PCA), 
in which the first two dimensions (Component 1, 27.1% vari-
ance; Component 2, 16.4% variance) noticeably separated the 
samples according to the protocol, while no separation between 
RA and healthy donors was detected (Figure 5B).
To unravel potential effects of RA on gene expression, which 
might have been missed by the previously applied three-factor 
model, we performed pairwise comparisons between RA- and 
healthy donor-derived DCs separately for each protocol. Only 
when comparing untreated DCs (iDCs) of RA patients and 
healthy controls (HCs), the analysis revealed 44 DE transcripts 
(Figure 5C). Differences in the expression of these genes were 
also present in mDCs, albeit not significant, and completely 
disappeared in tDCs and MPLA-tDCs (Figure  5C). Among 
these 44 DE genes, we identified 12 genes with known associa-
tion to RA (Figure 5C; Table S2 in Supplementary Material) due 
to their involvement in inflammatory processes, such as NF-kB 
activation (BCL10, MAP3K7/TAK1, MAPK1/ERK), inflamma-
tion (ALOX15, MAPK1/ERK, ATG3, ATXN3, VCL), induc-
tion of differentiation and/or activation of Th17 cells (BCL10, 
CD200R1), as well as chemotaxis and cellular infiltration of 
synovia (CCR2, CD200R1, SPN/CD43) (36–40). In contrast 
to HCs, the expression of these RA-associated genes changed 
markedly in DCs upon modulation with dexamethasone alone 
or in combination with MPLA (Figures  5C,D). Expression of 
RA-associated genes, which were upregulated in iDCs of RA 
patients, declined to levels of HCs in RA-derived MPLA-tDCs. 
Therefore, modulation with dexamethasone and MPLA removed 
differences at transcriptional level between moDCs from RA 
patients and healthy individuals.
FigUre 4 | MPla-tDcs modulate cD4+ T cell responses to synovial antigens. Monocytes (n = 6–9) were differentiated into mDCs and MPLA-tDCs as 
described in the Section “Materials and Methods.” At day 4 of DC generation, 4 h prior to stimulation with MPLA, mDCs and MPLA-tDCs were loaded with 1 μg/ml 
tuberculin purified protein derivative (PPD), 200 μg/ml synovial fluid (SF), or left unloaded for further 24 h. For the assessment of their T cell-stimulatory capacity, 
antigen-loaded or unloaded mDCs and MPLA-tDCs were co-cultured with autologous CFSE-labeled CD4+ T cells in a ratio of 1:2 (DC:T cell) for 6 days. To detect 
IFN-γ intracellularly, cells were stimulated with 50 ng/ml phorbol-12-myriastate-13-acetate and 1 μg/ml ionomycin in the presence of 1 μg/ml brefeldin-A. 
Proliferation-associated CFSE dilution and IFN-γ production of CD4+ T cells were analyzed by flow cytometry. (a) Representative dot plots and (B) graphic 
representation of the percentage of IFN-γ-producing proliferating (CFSElow) CD4+ T cells are shown. (c) IL-17A secretion was measured in supernatants of 
co-cultures by ELISA. (B,c), Box plots show median, 25- and 75%-quartiles and both extreme values (*P < 0.05).
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DiscUssiOn
As prerequisite for clinical trials using TolDCs for RA therapy, 
differentiation protocols have to be tested with cells from 
patients. Here we demonstrate that treatment with dexametha-
sone and MPLA overcomes disease-associated effects on gene 
transcription in moDCs and promotes a tolerogenic phenotype 
with reduced capacity to induce inflammatory responses in 
antigen-specific T cells.
Dexamethasone, a corticosteroid widely used to treat autoim-
mune disorders, has been shown to modulate maturation and 
function of DCs in vitro and in vivo, validating its use for TolDC 
generation (41, 42). Additionally, activation through TLR4 is 
required to endow TolDCs with the ability to process and present 
exogenous antigen on MHC class II molecules and to acquire 
the capacity to migrate to secondary lymphoid tissues, the sites 
of interaction with naïve T cells (43). Functionally, glucocor-
ticoids, such as dexamethasone, suppress pro-inflammatory 
programs induced by TLR activation, while potentiating TLR-
induced anti-inflammatory responses (44, 45). To meet cGMP 
requirements, we used the non-toxic TLR4 ligand, MPLA, 
instead of LPS, for DC activation. MPLA exhibits a potent 
immunostimulatory capacity (46), albeit less than LPS, and has 
been proven to be an effective and safe adjuvant in animal studies 
and clinical trials testing next-generation vaccines (43, 47). We 
previously demonstrated that dexamethasone-modulated and 
MPLA-activated DCs display a similar tolerogenic phenotype as 
DCs treated with dexamethasone alone, indicating that MPLA 
does not affect immunoregulatory properties of dexamethasone-
conditioned DCs (20). Stoop and co-workers also demonstrated 
in an experimental arthritis model that DCs modulated with 
dexamethasone and vitamin D3, and activated with LPS retained 
their tolerogenic functions, even in a pro-inflammatory environ-
ment in vivo (48). According to previous reports describing the 
properties of TolDCs derived from healthy donors (31, 43), 
MPLA-tDCs from RA patients showed reduced expression of 
co-stimulatory molecule CD86, the coactivator CD40, and the 
maturation marker CD83, as well as high expression of MHC 
class II, similar to mDCs. Since these cells will encounter a highly 
pro-inflammatory environment when transferred into RA 
patients, it is crucial that they are able to retain their regulatory 
features under these conditions. Exposure of MPLA-tDCs to 
inflammatory stimuli, such as TNF and SF, which are also present 
in RA, did not affect their tolerogenic phenotype. Accordingly, 
their capacity to induce hyporresponsiveness of autologous 
CD4+ T cells was not impaired upon challenge with SF. The anti-
inflammatory cytokine profile of MPLA-tDCs from RA patients 
points to their immunomodulatory abilities. Correspondingly, 
RA patient-derived MPLA-tDCs did not promote Th1 and Th17 
responses, probably due to reduced IL-12p70 and IL-23 produc-
tion, and the suppressive effect of other MPLA-tDC-derived 
molecules, such as IL-10 and TGF-β. This induction of T cell 
8García-González et al. Tolerogenicity of MPLA-tDCs from RA-Patients
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 458
FigUre 5 | conditioning with dexamethasone and MPla induces similar transcriptional profiles on monocyte-derived Dcs from rheumatoid arthritis 
patients and healthy controls and counterpoints disease-associated effects on gene expression. (a) Venn diagram displaying numbers of differentially 
expressed (DE) transcripts due to differentiation protocol (iDCs, mDCs, tDCs, or MPLA-tDCs), presence of disease (healthy controls: HC, or rheumartoid arthritis: 
RA) or interaction of protocol and disease. (B) Principal component analysis using the first two components separates samples according to their variance. (c,D) 
Pairwise comparison between moDCs from RA patients and HC were performed for each differentiation protocol separately using t-test. (c) 44 DE genes found 
exclusively in iDCs were hierarchically clustered. Genes with known or potential association to RA are highlighted in red color. (D) Changes in means of expression of 
selected RA-associated DE genes in iDCs vs. MPLA-tDCs were shown for HC and RA patients. iDCs, unstimulated immature DCs; tDCs, dexamethasone-
modulated TolDCs; mDCs, MPLA-matured DCs; MPLA-tDCs, dexamethasone-modulated MPLA-activated TolDCs.
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hyporesponsiveness is in accordance with our recent findings, 
unraveling that MPLA-tDCs from HCs do not promote classical 
Treg, but rather induce hyporesponsive anergic T cells capable 
of suppressing Th1 and Th17 responses (49).
Lymph node trafficking is a critical feature of TolDCs when 
intended to use for cellular therapy in autoimmunity (50). We 
showed that a significant proportion of MPLA-tDCs from RA 
patients expressed lymph node homing receptors CCR7 and 
CXCR4 and migrated in vitro in response to CCL19 and CXCL12, 
albeit less than mDCs. It is conceivable that inoculated MPLA-
tDCs might exert their tolerogenic functions not only in lymph 
nodes but also locally within the inflamed joint, since it has 
been shown that dexamethasone-treated LPS-activated TolDCs 
express also CXCR3 and migrate toward its ligand CXCL10/IP10 
associated with inflamed tissues (51).
The capacity of TolDCs to present antigen in a MHC class 
II context is critical for the induction of auto-antigen-specific 
tolerance (18). The fact that MPLA-tDCs from RA patients 
express HLA-DR in amounts comparable to mDCs indicates that 
dexamethasone does not affect antigen presentation and that the 
poor T cell stimulatory capacity exhibited by MPLA-tDCs in 
allogeneic and autologous settings might rather be due to their 
anti-inflammatory properties than to an impairment of antigen 
presentation. We have recently demonstrated that MPLA-tDCs 
derived from HLA-DRB1*0101+ RA patients are capable of 
efficiently presenting collagen peptide hCII(259–273) to the 
HLA-DR-restricted T cell hybridoma HCII-9.1 (49). Here, we 
demonstrate that MPLA-tDCs from RA patients are furthermore 
able to maintain their phenotypic features under inflammatory 
conditions and to induce hyporesponsiveness of autologous 
CD4+ T cells with specificity to synovial antigens. This is crucial 
considering that Th17 and Th1 responses lead to the progression 
of RA (52).
Monocytes from RA patients are highly activated and 
inflammatory (28, 29), suggesting that an early transcriptional 
program in monocytes might favor the development of highly 
inflammatory DCs in vivo and in vitro. This might also interfere 
with the acquirement of regulatory functions when generating 
TolDCs. Estrada-Capetillo and colleagues reported that moDCs 
from RA patients release high amounts of IL-6 and IL-23, and 
exhibit an increased capability to induce Th17 cells, while 
RA-derived TolDCs failed to induce Treg (30). However, Dr. 
Hilkens’ group (31) and we have demonstrated that TolDCs 
generated from monocytes of RA patients possess tolerogenic 
features comparable to those of healthy individuals. The con-
tradictory results concerning TolDC functionality lead us to 
further investigate these cells to a transcriptional level in order 
to identify or discard differences in gene expression between 
RA and HCs that could interfere with TolDC differentiation 
and function. Whole-genome expression analysis allowed us 
to confirm at a transcriptional level that treatment of moDCs 
with dexamethasone plus MPLA is sufficient to overcome 
RA-associated effects on gene expression in these cells. Despite 
individual data scattering, the transcriptional program of 
MPLA-tDCs remains consistent and allows clear separation 
from other DCs populations, particularly from untreated (iDCs) 
and mDCs, which still present disease-related effects on gene 
expression. This is in accordance with the absence of phenotypic 
and functional differences between MPLA-tDCs of RA patients 
and healthy subjects and suggests that MPLA-tDCs are suitable 
for autologous cellular therapy of RA.
cOnclUsiOn
Combined treatment with dexamethasone and MPLA over-
comes RA-associated alterations in gene expression and induces 
TolDCs with a stable semi-mature phenotype, which migrate 
toward lymphoid chemokines, secrete regulatory cytokines, 
and induce hyporesponsiveness of synovial antigens-specific 
T cells. Thus, MPLA-tDCs are eligible for the development of 
an autologous tolerance-inducing cellular therapy for the treat-
ment of RA.
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